Vinay Mathew Thomas

Also affiliated with Huntsman Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial”.

Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial

BMC Cancer(2024)10.1186/s12885-024-12260-3

N/A

0.278DataRank · unranked

4 citations

Lea Haverbeck Simon, Kelsey E. Maslana, Sarah Taylor, Kish Larson, Pamela A. Hansen +9 more

Predictors of response to neoadjuvant therapy in urothelial cancer

Critical Reviews in Oncology/Hematology(2023)10.1016/j.critrevonc.2023.104236

N/A

0DataRank · unranked

9 citations

Gliceida Galarza Fortuna, Georges Gebrael, Emre Dal, Vinay Mathew Thomas, Sumati Gupta +2 more

Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations

Kidney Cancer(2024)10.3233/kca-240016

N/A

0DataRank · unranked

4 citations

Georges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, Haoran Li, Gliceida Galarza Fortuna +11 more

Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy

European Urology Oncology(2024)10.1016/j.euo.2024.04.013

N/A

0DataRank · unranked

1 citations

Nicolas Sayegh, Beverly Chigarira, Georges Gebrael, Nishita Tripathi, Roberto Nussenzveig +10 more

First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma

Journal of Kidney Cancer and VHL(2025)10.15586/jkcvhl.v12i2.387

N/A

0DataRank · unranked

3 citations

Yeonjung Jo, Georges Gebrael, Chadi Hage Chehade, Zeynep İrem Özay, Blake Nordblad +11 more